Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Free Cash Flow: 2020-2025

Historic Free Cash Flow for Lyell Immunopharma (LYEL) over the last 5 years, with Sep 2025 value amounting to -$28.6 million.

  • Lyell Immunopharma's Free Cash Flow rose 18.41% to -$28.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$165.5 million, marking a year-over-year decrease of 5.95%. This contributed to the annual value of -$162.9 million for FY2024, which is 2.12% up from last year.
  • According to the latest figures from Q3 2025, Lyell Immunopharma's Free Cash Flow is -$28.6 million, which was up 17.29% from -$34.6 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Free Cash Flow registered a high of -$28.6 million during Q3 2025, and its lowest value of -$58.4 million during Q2 2021.
  • Moreover, its 3-year median value for Free Cash Flow was -$40.1 million (2023), whereas its average is -$40.7 million.
  • As far as peak fluctuations go, Lyell Immunopharma's Free Cash Flow grew by 22.15% in 2023, and later plummeted by 30.18% in 2025.
  • Lyell Immunopharma's Free Cash Flow (Quarterly) stood at -$43.5 million in 2021, then dropped by 3.15% to -$44.8 million in 2022, then rose by 9.34% to -$40.7 million in 2023, then decreased by 16.30% to -$47.3 million in 2024, then grew by 18.41% to -$28.6 million in 2025.
  • Its Free Cash Flow stands at -$28.6 million for Q3 2025, versus -$34.6 million for Q2 2025 and -$55.0 million for Q1 2025.